

CITATION REPORT

List of articles citing

Effect of obesity on the pharmacokinetics of drugs in humans

DOI: 10.2165/11318100-0000000000-000000
Clinical Pharmacokinetics, 2010, 49, 71-87.

Source: <https://exaly.com/paper-pdf/49369821/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
531	Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. 2010 , 54, 4605-10		133
530	Dose adjustment of anaesthetics in the morbidly obese. 2010 , 105 Suppl 1, i16-23		272
529	Prevention of venous thromboembolism in obesity. 2010 , 8, 1711-21		80
528	Dosing ethambutol in obese patients. 2010 , 54, 4044; author reply 4044-5		5
527	Estimating the glomerular filtration rate in obese adult patients for drug dosing. 2010 , 17, e53-62		87
526	Obesity may have clinically important effects on the pharmacokinetics of some drugs. 2010 , 26, 24-26		
525	Journal Watch. 2010 , 24, 59-70		
524	Gestione perioperatoria del paziente obeso. 2011 , 16, 1-10		
523	The effects of obesity on drug pharmacokinetics in humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 697-706	5.5	67
522	Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 739-50	6.2	56
521	Obesity and allometric scaling of pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 751-3; discussion 755-6	6.2	39
520	Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 809-22	6.2	52
519	Obesity and its impact on drug therapy: are we ready for this change?. <i>Clinical Pharmacokinetics</i> , 2011 , 50, 825-6	6.2	
518	Implications of obesity for drug therapy: limitations and challenges. 2011 , 90, 77-89		140
517	Is antiarrhythmic treatment in the elderly different? a review of the specific changes. 2011 , 28, 617-33		22
516	Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. 2011 , 51, 1376-402		64
515	Physiologically-based pharmacokinetics in drug development and regulatory science. 2011 , 51, 45-73		472

514	Endocrine disrupting chemicals and other substances of concern in food contact materials: an updated review of exposure, effect and risk assessment. 2011 , 127, 118-27	132
513	Perioperative evaluation of the obese patient. 2011 , 23, 575-86	25
512	Manejo perioperatorio del paciente obeso. 2011 , 37, 1-11	
511	Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. 2011 , 23, 845-51	23
510	The effect of obesity and anesthetic maintenance regimen on postoperative pulmonary complications. 2011 , 113, 4-6	4
509	Prise en charge périopératoire du patient obèse. 2011 , 8, 1-10	
508	Anticoagulating obese patients in the modern era. 2011 , 155, 137-49	75
507	Patient variation in veterinary medicine--part II--influence of physiological variables. 2011 , 34, 209-23	20
506	Anaesthesia for adults undergoing non-bariatric surgery. 2011 , 25, 37-51	10
505	Drug dosing and monitoring in obese patients undergoing allogeneic stem cell transplantation. <i>International Journal of Clinical Pharmacy</i> , 2011 , 33, 918-24	2,3 6
504	Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. 2011 , 67, 493-506	45
503	Antifungal Dosing in Obesity: A Review of the Literature. 2011 , 5, 83-91	4
502	Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. 2011 , 13, 406-15	23
501	On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. 2011 , 100, 2482-97	15
500	Antibiotic dosing in critical illness. 2011 , 66 Suppl 2, ii25-31	73
499	Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. 2011 , 66, 2330-5	39
498	Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). 2011 , 66, 2083-91	24
497	Micafungin therapy in a critically ill, morbidly obese patient. 2011 , 66, 2678-80	13

496	Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. 2011 , 113, 730-7		77
495	Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy. 2011 , 4, 238-43		25
494	Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient. 2011 , 66, 1653-4		14
493	Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. 2011 , 55, 5640-5		24
492	Innovative clinical trial design for pediatric therapeutics. 2011 , 4, 643-52		83
491	Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. 2011 , 55, 2601-5		38
490	Clinical and critical care concerns in severely ill obese patient. 2012 , 16, 740-8		13
489	The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. 2012 , 169, 256-63		67
488	Optimal meropenem concentrations to treat multidrug-resistant <i>Pseudomonas aeruginosa</i> septic shock. 2012 , 56, 2129-31		64
487	Dosing of antibiotics in obesity. 2012 , 25, 634-49		100
486	Obesity and low back pain: relationships and treatment. 2012 , 2, 79-86		9
485	Estimation of body weight in hospitalized patients. 2012 , 105, 769-74		17
484	The effects of gastric bypass surgery on drug absorption and pharmacokinetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1505-19	5.5	38
483	Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 481-499	6.2	79
482	Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review. 2012 , 136, 323-30		22
481	Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. 2012 , 30, 1553-61		358
480	Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. 2012 , 31, 1771-4		25
479	Impact of obesity on drug metabolism and elimination in adults and children. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 277-304	6.2	226

478	Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. 2012 , 18, 837-44	8
477	Measuring altered disposition of xenobiotics in experimental models of liver disease. 2012 , Chapter 23, Unit 23.1.	2
476	The impact of obesity on the immune response to infection. 2012 , 71, 298-306	258
475	Physiological Model for Distribution. 2012 , 89-117	1
474	Variability, Uncertainty, and Sensitivity Analysis. 2012 , 161-181	4
473	Physiologically-Based Pharmacokinetic Modeling of Populations. 2012 , 383-399	
472	Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. 2012 , 5, 69-89	60
471	Body mass index influences the response to infliximab in ankylosing spondylitis. 2012 , 14, R115	73
470	Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. 2012 , 2012, 376721	37
469	Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. 2012 , 67, 1305-10	61
468	Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. 2012 , 68, 961-8	32
467	Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. 2012 , 35, 335-41	82
466	A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer. 2012 , 39, 1-8	5
465	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. 2012 , 10, 1220-30	171
464	Analgesic concentrations of oxycodone--a prospective clinical PK/PD study in patients with laparoscopic cholecystectomy. 2012 , 110, 469-75	37
463	The influence of fatty acids on theophylline binding to human serum albumin. Comparative fluorescence study. 2012 , 89, 270-5	7
462	Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity. 2012 , 261, 189-95	12
461	Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology. 2012 , 73, 685-90	28

460	Effect of blood protein concentrations on drug-dosing regimes: practical guidance. 2013 , 10, 20	10
459	Chemotherapy dosing in overweight and obese patients with cancer. 2013 , 10, 451-9	62
458	Body mass index and bioelectrical impedance phase angle as potentially modifiable nutritional markers are independent risk factors for outcome in allogeneic hematopoietic cell transplantation. 2013 , 92, 111-9	39
457	Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients. 2013 , 71, 175-82	10
456	Prolonged benzodiazepine coma as a complication of morbid obesity. 2013 , 23, 1452-3	2
455	Challenges in the optimisation of post-operative pain management with opioids in obese patients: a literature review. 2013 , 23, 1458-75	30
454	Care of the Bariatric Patient in Acute Care. 2013 , 32, 21-31	3
453	Features of cancer management in obese patients. 2013 , 85, 193-205	6
452	Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions. 2013 , 40, 623-38	13
451	Preoperative risk reduction: strategies to optimize outcomes. 2013 , 93, 1041-55	51
450	Pharmacologic prevention of venous thromboembolism in obese patients. 2013 , 36, 247-57	13
449	Pharmacokinetic study of major bioactive components in rats after oral administration of extract of <i>Ilex hainanensis</i> by high-performance liquid chromatography/electrospray ionization mass spectrometry. 2013 , 77, 21-8	24
448	Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. 2013 , 53, 119-39	45
447	Objectifs pharmacocinétiques, pharmacodynamiques (PK/PD) et adaptation posologique des antibiotiques chez le patient de réanimation : vers une approche pratique. 2013 , 83-103	
446	Endotherapy for and tailored approaches to treating GERD, and refractory GERD. 2013 , 1300, 166-186	8
445	Management of Obesity in Older People. 2013 , 43, 145-149	
444	Attitudes and opinion about adverse drug events of women living in a city of south Italy. 2013 , 91, 173-7	5
443	Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. 2013 , 54, 541-6	24

442	Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. 2013 , 48, 210-9		40
441	A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. 2013 , 33, 479-84		42
440	Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. 2013 , 57, 1672-6		46
439	Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant <i>Staphylococcus aureus</i> pneumonia: case report and review of the literature. 2013 , 47, e25		22
438	On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?. 2013 , 88, 56-63		6
437	Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn. 2013 , 25, 1450-5		6
436	Inadequate therapeutic response to a recommended antituberculosis fixed-dose combination regimen in an overweight patient with <i>Mycobacterium bovis</i> infection. 2013 , 47, e4		1
435	Identifying determinants of variability to tailor aspirin therapy. 2013 , 11, 365-79		20
434	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. 2013 , 8, 871-890		8
433	Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?. 2013 , 25, 543-9		51
432	Antithrombotic therapy in obesity. 2013 , 110, 681-8		20
431	Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010. 2013 , 10, 1665-73		9
430	Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 919-30	6.2	34
429	Pharmacogenomics of episodic migraine: time has come for a step forward. 2014 , 15, 541-9		10
428	Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid. 2014 , 103, 2571-84		4
427	Increase in body mass index from normal weight to overweight in a cross-sectional sample of healthy research volunteers. 2014 , 34, 1052-7		4
426	Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. 2014 , 39, 584-608		51
425	Body mass index as a prognostic factor in organophosphate-poisoned patients. 2014 , 32, 693-6		10

424	Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. 2014 , 34, 28-35		33
423	Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. 2014 , 171, 580-94		127
422	Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. 2014 , 99, 1314-21		32
421	Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration. 2014 , 34, e162-8		9
420	Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥ 40 kg/m ²) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 753-62	6.2	23
419	Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. 2014 , 54, 324-30		28
418	Obesity during pregnancy alters maternal oxidant balance and micronutrient status. 2014 , 34, 105-11		50
417	H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice. 2014 , 307, G219-28		13
416	Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. 2014 , 14, 128		4
415	Nutritional management of idiopathic epilepsy in dogs. 2014 , 245, 504-8		8
414	[Antiplatelet therapy: resistance to traditional antiaggregation drugs and role of new antiplatelet agents]. 2014 , 143, 222-9		2
413	The effect of molecular subtype and body mass index on neo-adjuvant chemotherapy in breast cancer patients. 2014 , 23, 264-72		8
412	Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. 2014 , 44, 1108-16		9
411	Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. 2014 , 111, 258-65		11
410	Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review. 2014 , 6, 227-33		10
409	A simple introduction to pharmacokinetics: Part 1. 2014 , 12, 497-503		3
408	Volume of distribution - Again. 2014 , 3, 419-20		4
407	Dapsone and body mass index in subjects with multibacillary leprosy. 2014 , 36, 261-3		5

406	Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients. 2015 , 55, 899-908	21
405	The potential for nutritional components of food items used for enrichment of research animals to act as confounding variables in toxicology studies. 2015 , 44, 222-33	0
404	Besonderheiten der Pharmakotherapie adipöser Patienten. 2015 , 15, 45-50	
403	Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. 2015 , 15, 71	275
402	Risk of breast cancer in relation to combined effects of hormone therapy, body mass index, and alcohol use, by hormone-receptor status. 2015 , 26, 353-61	20
401	Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review. 2015 , 26, 655-60	14
400	Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia. 2015 , 25, 734-40	3
399	Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. 2015 , 58, 432-6	50
398	The Impact of Body Mass Index on the Surgical Outcomes of Patients With Gastric Cancer: A 10-Year, Single-Institution Cohort Study. 2015 , 94, e1769	64
397	Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. 2015 , 68, 33-47	49
396	Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre. 2015 , 12, 334-40	11
395	Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections. 2016 , 8, 1-8	17
394	Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review. 2015 , 10, e0122047	23
393	Individualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic review. 2015 , 10, e0116403	9
392	Vitamin paradox in obesity: Deficiency or excess?. 2015 , 6, 1158-67	26
391	Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. 2015 , 4, 32	7
390	Peri-operative management of the obese surgical patient 2015: Association of Anaesthetists of Great Britain and Ireland Society for Obesity and Bariatric Anaesthesia. 2015 , 70, 859-76	148
389	How can we improve oral contraceptive success in obese women?. 2015 , 8, 1-3	1

388	Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era. 2015 , 56, 1959-68		13
387	The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control. 2015 , 31, 167-76		16
386	Prévention de la thrombose veineuse chez les patients obèses en réanimation. 2015 , 24, 46-55		
385	Adaptation posologique chez le sujet obèse. 2015 , 24, 367-378		
384	Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. 2015 , 138, 201-6		39
383	Body Mass Index and response to rituximab in rheumatoid arthritis. 2015 , 82, 432-6		28
382	Treatment of bacterial infections in obese adult patients: how to appropriately manage antimicrobial dosage. 2015 , 24, 12-7		13
381	Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease. 2015 , 9, 640-6		22
380	Assessing steatotic liver function after ischemia-reperfusion injury by in vivo multiphoton imaging of fluorescein disposition. 2015 , 43, 154-62		14
379	Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies. 2015 , 59, 5463-9		14
378	A Review of the Toxicologic Implications of Obesity. 2015 , 11, 342-54		18
377	Altered drug disposition following bariatric surgery: a research challenge. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 573-9	6.2	27
376	Assessing an enoxaparin dosing protocol in morbidly obese patients. 2015 , 39, 516-21		23
375	Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1203-17	5.5	11
374	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. 2015 , 29, 193-200		9
373	Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. 2015 , 151, 99-106		13
372	Feasibility of closed-loop co-administration of propofol and remifentanyl guided by the bispectral index in obese patients: a prospective cohort comparison. 2015 , 114, 605-14		25
371	Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 333-41	6.2	23

370	Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications. 2015 , 37, 1924-32		22
369	Development of a pharmacist-driven protocol for automatic medication dosage adjustments in obese patients. 2015 , 72, 1656-63		9
368	The Influence Of Obesity On Results Of AT (Doxorubicin Plus Docetaxel) Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer Patients. 2015 , 87, 231-7		6
367	Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis. 2015 , 92, 445-52		80
366	Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing. 2015 , 37, 1897-923		46
365	Concentration of amoxicillin in maternal serum, cord blood, amniotic fluid and the placenta after vaginal administration. 2015 , 28, 2048-52		0
364	Drug disposition in obesity: toward evidence-based dosing. 2015 , 55, 149-67		79
363	Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. 2015 , 95, 54-9		20
362	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. 2015 , 70, 891-8		50
361	Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 179-93	6.2	22
360	Role of Kupffer cells in ischemic injury in alcoholic fatty liver. 2015 , 194, 91-100		14
359	Perioperative physiology and pharmacology in the obese small animal patient. 2015 , 42, 119-32		15
358	Therapeutic Drug Monitoring in Obese Patients. 2016 , 231-243		
357	A Phase I study evaluating the effect of age and weight on the pharmacokinetics of an injectable formulation of diclofenac solubilized with hydroxypropyl-β-cyclodextrin. 2016 , 8, 203-212		
356	The Effect of Patient Weight and Provider Training and Experience on Dosing of Rocuronium. 2016 , 2016, 3136895		
355	Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients. 2016 , 36, 740-8		17
354	Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels. 2016 , 28, 271-6		22
353	Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose. 2016 , 30, 108-13		4

352	Creatinine-based equations for the adjustment of drug dosage in an obese population. 2016 , 81, 349-61	31
351	A high-fat high-energy diet influences hepatic CYP3A expression and activity in low-birth-weight developing female rats. 2016 , 12, 489-497	2
350	Evaluation of cephalexin failure rates in morbidly obese patients with cellulitis. 2016 , 41, 409-13	2
349	Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients. 2016 , 20, 205	6
348	Cefoxitin Plasma and Subcutaneous Adipose Tissue Concentration in Patients Undergoing Sleeve Gastrectomy. 2016 , 38, 204-10	3
347	Clinically Significant Interactions with Benzodiazepines. 2016 , 471-495	
346	Pharmacodynamics and Obesity. 2016 , 599-620	
345	Antibiotic dosing in obesity: a BIG challenge. 2016 , 20, 240	7
344	Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer. 2016 , 16, 480-486	10
343	Myelosuppression by chemotherapy in obese patients with gynecological cancers. 2016 , 78, 633-41	11
342	Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients. 2016 , 57, 2584-92	7
341	Can paracetamol (acetaminophen) be administered to patients with liver impairment?. 2016 , 81, 210-22	48
340	Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. 2016 , 81, 1103-12	15
339	Effect of antenatal betamethasone on blood glucose levels in women with and without diabetes. 2016 , 118, 98-104	33
338	Anti-infective Dosing for Obese Adult Patients: A Focus on Newer Drugs to Treat Methicillin-resistant Staphylococcus aureus Acute Bacterial Skin and Skin Structure Infections. 2016 , 38, 2032-44	10
337	Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. 2016 , 73, 9-15	23
336	Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. 2016 , 38, 1930-47	73
335	Body mass index and response to abatacept in rheumatoid arthritis. 2016 , 46, 1048-1052	19

334	Perioperative support reduces mortality of obese BALB/c mice after ovariectomy. 2016 , 45, 262-7	1
333	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. 2016 , 68, 297-306	99
332	Low-Molecular-Weight Heparin Prophylaxis Dosing: Is Weight an Issue?. 2016 , 32, 75-80	4
331	Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. 2016 , 35, 857-61	31
330	Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome. 2016 , 43, 383-7	43
329	Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers. 2016 , 13, 766-73	14
328	Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP. 2016 , 95, 409-16	8
327	A physiome interoperability roadmap for personalized drug development. 2016 , 6, 20150094	7
326	Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics. 2016 , 4, 357-60.e2	10
325	Obesity Does Not Affect Propofol Pharmacokinetics During Hypothermic Cardiopulmonary Bypass. 2016 , 30, 876-83	5
324	Doripenem Treatment during Continuous Renal Replacement Therapy. 2015 , 60, 1687-94	9
323	Obesity and lower limb venous disease - The epidemic of phlebesity. 2017 , 32, 227-233	33
322	Indice de masse corporelle et réponse au rituximab dans la polyarthrite rhumatoïde. 2017 , 84, 37-41	
321	Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. 2017 , 72, 1137-1146	10
320	Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. 2017 , 37, 361-378	20
319	The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. 2017 , 18, 1-76	242
318	Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia. 2017 , 98, 443-449	5
317	IV fosphenytoin in obese patients: Dosing strategies, safety, and efficacy. 2017 , 7, 45-52	2

316	Impact of Norepinephrine Weight-Based Dosing Compared With Non-Weight-Based Dosing in Achieving Time to Goal Mean Arterial Pressure in Obese Patients With Septic Shock. 2017 , 51, 614-616		1
315	Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients. 2017 , 73, 837-842		4
314	Preoperative Optimization and Enhanced Recovery Protocols in Ventral Hernia Repair. 2017 , 201-210		
313	Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects. 2017 , 57, 1290-1294		8
312	Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 625-640	5-5	14
311	Differential effects of liver steatosis on pharmacokinetic profile of two closely related hepatoselective NO-donors; V-PYRRO/NO and V-PROLI/NO. 2017 , 69, 560-565		4
310	Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed. 2017 , 113, 191-194		9
309	No role for patient body weight on renal function assessment for drug dosing. 2017 , 72, 1802-1811		3
308	Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China. 2017 , 58, 1624-1629		8
307	Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. 2017 , 14, 501-507		43
306	Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. 2017 , 23, 1853-1859		15
305	Hypertension in Obesity and the Impact of Weight Loss. 2017 , 19, 98		48
304	Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. 2017 , 31, 813-820		10
303	Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically ill patients. 2017 , 44, 386-391		8
302	Comprehensive Guidance for Antibiotic Dosing in Obese Adults. 2017 , 37, 1415-1431		70
301	Fixed Dosing of Monoclonal Antibodies in Oncology. 2017 , 22, 1212-1221		82
300	Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging. 2017 , 61,		6
299	Drug Dosing in Obese Children: Challenges and Evidence-Based Strategies. 2017 , 64, 1417-1438		11

298	Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin. 2017 , 15, 1704-1713		61
297	Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 561-571	6.2	13
296	Disparities in hemodynamic resuscitation of the obese critically ill septic shock patient. 2017 , 37, 219-223		16
295	Clarification of contraceptive drug pharmacokinetics in obesity. 2017 , 95, 10-16		14
294	Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients. 2017 , 57, 356-368		16
293	BMI as a Predictor of Spinal Cord Stimulation Success in Chronic Pain Patients. 2017 , 20, 269-273		18
292	Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. 2017 , 9,		14
291	Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk - a randomised, controlled trial. 2018 , 14, 773-780		9
290	A Review of the Field on Children's Exposure to Environmental Contaminants: A Risk Assessment Approach. 2017 , 14,		37
289	Population Pharmacoeigenomics. 2017 , 511-516		
288	Growth hormone prescribing and initial BMI SDS: Increased biochemical adverse effects and costs in obese children without additional gain in height. 2017 , 12, e0181567		4
287	Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. 2017 , 16, 67		16
286	Drug dosing in obese adults. 2017 , 40, 189-193		43
285	Anesthesia for Bariatric Surgery. 2017 , 77-84		1
284	Impact of antenatal corticosteroids in preterm neonates based on maternal body mass index. 2018 , 38, 813-819		3
283	The Effect of Obesity on Reproductive Health. 2018 , 123-142		
282	Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism. 2018 , 133, 170-186		40
281	The AAHKS Clinical Research Award: Intraosseous Regional Prophylaxis Provides Higher Tissue Concentrations in High BMI Patients in Total Knee Arthroplasty: A Randomized Trial. 2018 , 33, S13-S18		18

280	Effect of tumor necrosis factor inhibitors on spinal radiographic progression in patients with ankylosing spondylitis. 2018 , 21, 1098-1105		14
279	Higher chlorzoxazone clearance in obese children compared with nonobese peers. 2018 , 84, 1738-1747		17
278	Four-week individual caging of male ICR mice alters body composition without change in body mass. 2018 , 8, 1331		2
277	Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery. 2018 , 131, 211-217		5
276	Perioperative Care of the Obese Cardiac Surgical Patient. 2018 , 32, 1911-1921		8
275	Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 275-285	5.5	66
274	Obesity and Pediatric Drug Development. 2018 , 58, 650-661		13
273	Solving the problem of dose optimization of children's medicines. 2018 , 11, 205-208		2
272	Sedation of the Obese Patient: Indications, Management, and Complications. 2018 , 123-138		
271	Effect of body weight and composition on efavirenz, atazanavir or darunavir concentration. 2018 , 73, 185-191		2
270	Anesthetic and pharmacologic considerations in perioperative care of obese children. 2018 , 45, 39-50		18
269	Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers. 2018 , 62,		11
268	Pharmacokinetics of amlodipine besylate at delivery and during lactation. 2018 , 11, 77-80		10
267	Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study. 2018 , 6, e00398		11
266	High-Fat Diets Alter the Modulatory Effects of Xenobiotics on Cytochrome P450 Activities. 2018 , 31, 308-318		21
265	Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. 2018 , 38, 172-179		8
264	Enoxaparin Dosing at Extremes of Weight: Literature Review and Dosing Recommendations. 2018 , 52, 898-909		27
263	A randomized comparison of intravenous sedation using a dosing algorithm compared to standard care during first-trimester surgical abortion. 2018 , 97, 490-496		2

262	A Phase 1 Randomized, Placebo-Controlled Study Assessing the Pharmacokinetics, Safety, and Tolerability of Retosiban in Healthy, Nonpregnant Japanese Subjects. 2018 , 7, 59-66		
261	Influence of the recipient body mass index on the outcomes after kidney transplantation. 2018 , 403, 73-82		8
260	Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 989-1000	6.2	12
259	Sedation for Endoscopy in the Obese Patient. 2018 , 23-37		
258	Apremilast in psoriasis - a prospective real-world study. 2018 , 32, 254-259		43
257	Relation Between TRCA Complication Rates and Peak ACT Levels Stratified According to the BMI Tertiles. 2018 , 69, 400-405		
256	Challenges to Safe and Effective Pain Management in Patients With Super Obesity: Case Report and Literature Review. 2018 , 55, 1047-1052		4
255	Obesity and Altered Aspirin Pharmacology. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 663-672	6.2	16
254	Enhanced Recovery Pathway for Complex Abdominal Wall Reconstruction. 2018 , 142, 133S-141S		7
253	Micafungin and caspofungin pharmacodynamics in patients with candidemia. 2018 , 10, 36-47		
252	Adverse drug reactions. 2018 , 363, k4051		8
251	Chemoresistance: Intricate Interplay Between Breast Tumor Cells and Adipocytes in the Tumor Microenvironment. 2018 , 9, 758		19
250	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. 2018 , 10, 116		11
249	Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial. 2018 , 12, 516-522		5
248	Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications. 2018 , 10, 63-70		4
247	Sex and body weight are major determinants of venlafaxine pharmacokinetics. 2018 , 33, 322-329		7
246	Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. 2018 , 19,		23
245	Overcoming multiple drug resistance in cancer using polymeric micelles. 2018 , 15, 1127-1142		24

244	Preoperative Optimization and Enhanced Recovery After Surgery Protocols in Ventral Hernia Repair. 2018 , 21-32	
243	Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. 2018 , 98, 1-9	20
242	Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies. 2018 , 38, 673-693	5
241	Protein and Tissue Binding: Implication on Pharmacokinetic Parameters. 2018 , 371-399	0
240	Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. 2018 , 129, 102-112	31
239	Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial. 2018 , 19, 207	14
238	Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. 2018 , 58, 1436-1442	9
237	Effect of obesity on biodistribution of nanoparticles. 2018 , 281, 11-18	14
236	Anticoagulation at the extremes of body weight: choices and dosing. 2018 , 11, 817-828	12
235	Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety. 2018 , 38, 289-295	13
234	Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments. 2018 , 43, 829-835	1
233	Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children. 2019 , 21, 357-369	9
232	Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. 2019 , 74, 2681-2689	2
231	The association of pregnane X receptor activation with outcomes after liver transplantation-A retrospective study. 2019 , 33, e13734	1
230	Body mass index at diagnosis is associated with survival outcome in peripheral T-cell lymphoma: a study of Chinese population. 2020 , 50, 169-174	
229	Spondyloarthritis et obésité : l'impact des anti TNF : essayer le « switch » du site d'injection sous cutané avant de « switcher » de biomédicament ? Commentaire de l'article de Shan et al. : influence de l'obésité sur l'efficacité de différents agents biologiques dans les maladies inflammatoires : revue systématique et méta-analyse. <i>Revue du rhumatisme</i> 2019;86:326-36. 2019 , 86, 347-349	
228	Polymeric Carriers for Controlled Drug Delivery in Obesity Treatment. 2019 , 30, 974-989	14
227	Thoracic Anesthesia for Morbidly Obese Patients and Obese Patients with Obstructive Sleep Apnea. 2019 , 545-559	

226	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. 2019 , 31, 34-42	34
225	Evaluation of treatment options for methicillin-resistant infections in the obese patient. 2019 , 12, 877-891	3
224	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. 2019 , 23, 205	15
223	Oxytocin and Oxytocinase in the Obese and Nonobese Parturients during Induction and Augmentation of Labor. 2019 , 9, e177-e184	0
222	Diet-induced obese alters the expression and function of hepatic drug-metabolizing enzymes and transporters in rats. 2019 , 164, 368-376	19
221	Antioxidation, hepatic- and renal-protection of water-extractable polysaccharides by Dictyophora indusiata on obese mice. 2019 , 134, 290-301	14
220	Insulin resistance accelerated the clearance of resveratrol: A note of caution. 2019 , 58, 311-323	
219	Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial. 2019 , 74, 2335-2340	7
218	Anti-Xa activity by weight in critically ill patients receiving unfractionated heparin for venous thromboembolism prophylaxis. 2019 , 52, 180-185	0
217	Impact of Non-cardiac Comorbidities in Adults with Congenital Heart Disease: Management of Multisystem Complications. 2019 , 433-455	
216	Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity. 2019 , 48, 387-393	6
215	Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review. 2019 , 48, 359-365	19
214	Influence de l'obésité sur l'efficacité de différents agents biologiques dans les maladies inflammatoires : revue systématique et méta-analyse. 2019 , 86, 326-336	
213	High-dose oral linezolid achieved rapid clinical and microbiological recovery in a severely overweight male with long-standing infected ulcers. 2019 , 74, 1755-1757	0
212	Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. 2019 , 71, 982-987	6
211	Altered pharmacokinetics of combined oral contraceptives in obesity - multistudy assessment. 2019 , 99, 256-263	10
210	Designer Benzodiazepines: A Review of Published Data and Public Health Significance. 2019 , 8, 266-269	18
209	Special Populations: Profiling the Effect of Obesity on Drug Disposition and Pharmacodynamics. 2019 , 1-25	0

208	Weight Loss Medications in the Treatment of Obesity and Hypertension. 2019 , 21, 16	31
207	Infection, Antimicrobial Drugs, and Anesthesia. 2019 , 769-780	1
206	Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity. 2019 , 9, 20405	10
205	Dosing of Continuous Fentanyl Infusions in Obese Children: A Population Pharmacokinetic Analysis. 2019 , 60, 636	4
204	Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia. 2019 , 74, 667-674	9
203	Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. 2019 , 368, 32-40	28
202	Repeat Intravenous Ketamine Dosing in Children Undergoing Emergency Department Procedural Sedation. 2019 , 56, 1-6	4
201	Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis. 2019 , 86, 173-183	44
200	[Hot rods in the ICU : What is the antibiotic mileage of your renal replacement therapy?]. 2019 , 114, 139-145	1
199	Is vaginal misoprostol more effective than oral misoprostol for cervical ripening in obese women?. 2020 , 33, 3476-3483	1
198	Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases. 2020 , 18, 2010-2018.e2	17
197	Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study. 2020 , 40, 33-40	6
196	Patients with Spondyloarthritis and obesity who fail TNF antagonist therapy: Change the subcutaneous injection site before the biologic? Comment on: "Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis" by Shan et al. <i>Joint Bone Spine</i> , 2019, 86, 173-183. 2020 , 87, 103-104	0
195	Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 475-483	6.2 3
194	Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 7-23	6.2
193	Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. 2020 , 301, 90-95	16
192	Association of Statin and Its Lipophilicity With Cardiovascular Events in Patients Receiving Chronic Dialysis. 2020 , 107, 1312-1324	2
191	Influence of obesity on pharmacokinetics and analgesic effect of ketoprofen administered intravenously to patients after laparoscopic cholecystectomy. 2020 , 72, 763-768	

190	Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy. 2020 , 125, 727-734		2
189	Modulation of expression/function of intestinal P-glycoprotein under disease states. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 59-78	5.5	11
188	Impact of Obesity on Ceftriaxone Efficacy. 2020 , 8,		3
187	The inhibition of hepatic Pxr-Oatp2 pathway mediating decreased hepatic uptake of rosuvastatin in rats with high-fat diet-induced obesity. 2020 , 257, 118079		1
186	Dosage adjustment in obese children, even for common drugs, is largely unclear and a treat-to-effect approach may work best. 2020 , 36, 341-346		
185	Procedural sedation in the morbidly obese: implications, complications, and management. 2020 , 58, 41-46		1
184	Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice. 2020 , 111, 415-418		
183	Obesity Trends Amongst Hospitalized Patients with Spinal Cord Stimulator Implants. 2020 , 37, 4614-4626		0
182	Losartan and azelastine either alone or in combination as modulators for endothelial dysfunction and platelets activation in diabetic hyperlipidemic rats. 2020 , 72, 1812-1821		2
181	Enhanced recovery for obese patients undergoing gynecologic cancer surgery. 2020 , 30, 1595-1602		2
180	Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 1551-1573	6.2	6
179	Clinical Pharmacology at the Intersection of Women's Health and Regulation: Drug Development Considerations for Uterine Fibroids. 2020 , 60 Suppl 2, S39-S48		2
178	Is Antimicrobial Dosing Adjustment Associated with Better Outcomes in Patients with Severe Obesity and Bloodstream Infections? An Exploratory Study. 2020 , 9,		1
177	Amoxicillin-induced crystal nephropathy: A nationwide French pharmacovigilance databases study. 2020 , 86, 2256-2265		9
176	Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice. 2020 , 111, 415-418		2
175	Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. 2020 , 77, 865-876		7
174	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. 2020 , 86, 1753-1768		2
173	The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients. 2020 , 20, 341		1

172	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. 2020 , 40, 287-292		12
171	Effect of Body Mass Index on Postoperative Nausea and Vomiting: Propensity Analysis. 2020 , 9,		5
170	Body mass index and treatment survival in patients with RA starting treatment with TNF α inhibitors: long-term follow-up in the real-life METEOR registry. 2020 , 6,		0
169	[Anti-infective treatment in obesity-"just double it?"]. 2020 , 69, 588-592		
168	Management of Neuromuscular Blockade in the Elderly and Morbidly Obese Patient: What Does the Data Show?. 2020 , 10, 107-116		
167	Unfractionated heparin dosing in obese patients. <i>International Journal of Clinical Pharmacy</i> , 2020 , 42, 462-473	2.3	0
166	Comparative study of anaesthesia induction in obese dogs using propofol dosages based on lean body weight or total body weight. 2020 , 10, 100131		2
165	Modern pharmacological treatment of obese patients. 2020 , 11, 2042018819897527		28
164	Impact of gastrointestinal physiology on drug absorption in special populations--An UNGAP review. 2020 , 147, 105280		63
163	The bone mineral density of hip joint was reduced in the initial stage of ankylosing spondylitis?. 2020 , 99, e19132		4
162	Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan. 2020 , 76, 723-729		2
161	Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder. 2020 , 267, 153-170		9
160	Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock. 2020 , 40, 211-220		2
159	Response to Comment on: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study". 2020 , 40, 289-290		
158	Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients. 2020 , 40, 479-483		1
157	Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study. 2020 , 9,		5
156	Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. 2021 , 51, 349-358		8
155	Median Effective Dose of Lidocaine for the Prevention of Pain Caused by the Injection of Propofol Formulated with Medium- and Long-Chain Triglycerides Based on Lean Body Weight. 2021 , 22, 1246-1252		0

154	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. 2021 , 87, 2602-2613		4
153	Pharmacokinetics of Sugammadex Dosed by Actual and Ideal Body Weight in Patients With Morbid Obesity Undergoing Surgery. <i>Clinical and Translational Science</i> , 2021 , 14, 737-744	4.9	0
152	Estimation of body surface area in neonates, infants, and children using body weight alone. 2021 , 8, 221-228		1
151	Effect of Obesity on Clinical Outcomes of Patients Treated With Cefepime. 2021 , 37, 30-35		1
150	Association of body mass index with toxicity and survival in pediatric patients treated with cisplatin-containing regimens. 2021 , 38, 239-250		2
149	Estimation of Body Fat Percentage for Clinical Pharmacokinetic Studies in Children. <i>Clinical and Translational Science</i> , 2021 , 14, 509-517	4.9	2
148	Effect of body mass index on intrauterine insemination cycle success. 2021 , 115, 221-228		3
147	Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. <i>Clinical and Translational Science</i> , 2021 , 14, 908-918	4.9	1
146	Dose, dosage regimen, and dose adjustment in organ failure. 2021 , 29-82		1
145	Pathophysiology of Obesity and Cancer: Drugs and Signaling Targets. 2021 , 43-63		
144	Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAf) patients with obesity in a US population. 2021 , 24, 550-562		2
143	Underweight and obesity are strong predictors of clinical outcomes in patients with ankylosing spondylitis: data from the Smart-phone SpondyloArthritis Management System. 2021 , 13, 1759720X211030792		
142	Pharmacokinetics of amoxicillin in obese and nonobese subjects. 2021 , 87, 3227-3233		3
141	Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Obesity. 2021 , 109, 942-951		0
140	Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. 2021 , 35, 273-278		2
139	Effect of lipophilicity on drug distribution and elimination: Influence of obesity. 2021 , 87, 3197-3205		9
138	Methotrexate Triglutamate as a Determinant of Clinical Response in Mexican Patients With Rheumatoid Arthritis: Pharmacokinetics and Dose Recommendation. 2021 , 61, 1118-1130		0
137	Evaluation of Dosing Strategies of N-acetylcysteine for Acetaminophen Toxicity in Patients Greater than 100 Kilograms: Should the Dosage Cap Be Used?. 2021 , 17, 241-249		2

136	Comparison of Outcomes in Patients with Obesity Between Two Administration Routes of Omeprazole After Laparoscopic Sleeve Gastrectomy: An Open-Label Randomized Clinical Trial. 2021 , 15, 1569-1576	0
135	Effect of Obesity on Clinical Failure of Patients Treated With β -Lactams. 2021 , 8, ofab212	3
134	A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients. 2021 , 12, 666348	1
133	Sex and Gender Differences in Clinical Pharmacology: Implications for Transgender Medicine. 2021 , 110, 897-908	8
132	Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations. 2021 , 46, 479-485	1
131	Looking for crumbs in the obesity forest: anti-obesity interventions in the Mexican population. History, and systematic review with Meta-Analysis.	
130	Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects. 2021 , 13,	1
129	Diagnostic and Treatment Challenges in Cerebral Tuberculoma in a Patient with Morbid Obesity. 2021 , 22, e932852	
128	Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Societ�Italiana Endocrinologia (SIE)/Societ�Italiana Farmacologia (SIF) multidisciplinary consensus position paper. 2021 , 6, 100153	3
127	The effect of weight and body mass index on serum progesterone values and live birth rate in cryopreserved in vitro fertilization cycles. 2021 , 2, 195-200	0
126	Effect of Roux-en-Y gastric bypass on the pharmacokinetic-pharmacodynamic relationships of liquid and controlled-release formulations of oxycodone. 2021 , 129, 232-245	
125	The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. 2021 , 23, 2502-2512	
124	Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity. 2021 , 23, 499-513	2
123	The Impact of Diet and Exercise on Drug Responses. 2021 , 22,	4
122	Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment. 2021 ,	1
121	How Antibiotics Stewardship Can Be Safely Implemented in Patients with Septic Shock?. 2021 , 42, 689-697	0
120	Impact of a hospital-wide computerised approach to optimise the quality of antimicrobial prescriptions in patients with severe obesity: a quasi-experimental study. 2021 , 21, 972	
119	Pooled Analysis of Gastric Emptying in Patients With Obesity: Implications for Oral Absorption Projection. 2021 , 43, 1768-1788	0

118	Help or hindrance: The obesity paradox in cancer treatment response. 2021 , 522, 269-280	2
117	Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO). 2021 , 10,	2
116	Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States. 2021 , 110, 3331-3344	6
115	Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD. 2021 , 27, 183-190	3
114	The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis. 2021 , 26, e12781	6
113	Basic Principles of Drug Delivery and Dosing. 2021 , 5-21	
112	Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. 2021 , 35, 261-272	9
111	Obesity and Multiple Myeloma. 2012 , 71-95	7
110	The Impact of Obesity on Pharmacokinetics and Dosing of Leukemia Chemotherapy. 2012 , 97-127	1
109	The Impact of Obesity on Stem Cell Transplant. 2012 , 129-140	1
108	Closed-Loop or Automated Titration of Intravenous Anesthesia: Background, Science, and Clinical Impact. 2017 , 649-666	1
107	Special Populations: Profiling the Effect of Obesity on Drug Disposition and Pharmacodynamics. 2020 , 723-747	1
106	How Should Obesity be Measured and How Should Anesthetic Drug Dosage be Calculated?. 2013 , 15-30	3
105	Liver Histological Improvement After Administration of High-Dose Vitamin C in Guinea Pig with Nonalcoholic Steatohepatitis. 2018 , 88, 263-269	3
104	Obesity is associated with folate metabolism. 2020 , 90, 353-364	5
103	Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials. 2020 , 7, ofaa548	1
102	The Role of Obesity in the Development and Management of Gynecologic Cancer. 2020 , 75, 308-316	2
101	Effects of oral glucosamine hydrochloride and mucopolysaccharide protein in a rabbit model of osteoarthritis. 2018 , 21, 620-628	6

100	Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). 2018 , 8, e021878		7
99	Adipocyte and lipid metabolism in cancer drug resistance. 2019 , 129, 3006-3017		103
98	New challenges in hemophilia: long-term outcomes and complications. 2012 , 2012, 362-368		28
97	Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. 2015 , 10, e0126767		28
96	Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism. 2019 , 4,		12
95	Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. <i>Clinical Pharmacokinetics</i> , 2012 , 51, 481-99	6.2	36
94	Choice of Perioperative Anesthetic Medications in Patients Undergoing Bariatric Surgery. 2019 , 25, 2115-2122	o	
93	Sexual Dimorphism in Drug Metabolism and Pharmacokinetics. 2019 , 20, 1154-1166		8
92	Low-Dose Urinary Human Chorionic Gonadotropin Is Effective for Oocyte Maturation in Fertilization/ Intracytoplasmic Sperm Injection Cycles Independent of Body Mass Index. 2017 , 11, 7-14		2
91	Effects of Obesity on Posaconazole Kinetics in a Patient with Graft versus Host Disease. 2013 , 04, 244-247		1
90	A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?. 2015 , 15, 1020-9		15
89	Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats. 2020 , 8, e9881		3
88	PHYSIOLOGICAL MODEL FOR DISTRIBUTION. 2021 , 169-192		
87	UNCERTAINTY AND POPULATION VARIABILITY. 2021 , 263-292		
86	Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	4
85	Adipocytic Glutamine Synthetase Upregulation Altered Histone Methylation Promotes 5FU Chemoresistance in Peritoneal Carcinomatosis of Colorectal Cancer. 2021 , 11, 748730		1
84	[Contraception in women with obesity]. 2021 , 37, 882-887		
83	Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes. 2021 , 208, 39-44		2

82	Parenteral Anticoagulants: Special Considerations in Patients with Chronic Kidney Disease and Obesity. 241-290	1
81	Pharmacogenomics and Personalized Medicine of the Antiplatelet Drugs. 2013 , 469-506	
80	Obesity in Critical Illness. 2014 , 57-68	
79	The Obese Patient. 2015 , 191-196	
78	20. A growing risk in a growing population: obesity's impact on leukemia incidence and survival. 2016 , 335-352	
77	Safe and effective antihypertensive therapy in obesity. 2016 , 12, 176-181	
76	Venous Thromboembolism Management in Obese Patients. 161-168	
75	Pharmakokinetik von Psychopharmaka nach Adipositaschirurgie. 2019 , 173-183	
74	Overweight and Obese Patients. 2019 , 493-498	
73	Effect of diabetic nephropathy on drug pharmacokinetics. 2018 , 14, 175-178	
72	CHAPTER 23:Khat, Betel, Coca and Tobacco Chewing: Genotoxic Effects in Micronucleus Assays. 2019 , 373-386	1
71	Glucocorticoids dosing in obese subjects: A systematic review. 2019 , 74, 451-458	3
70	Treatment for Pulmonary Embolism: Anticoagulation Selection and Duration. 2020 , 57-83	
69	The interference of polypharmacy and the importance of clinical pharmacy advice in the treatment of leprosy: a case-control study. 2020 , 53, e20200114	1
68	Cardiopulmonary resuscitation in obese patients. 2020 , 16, 21-28	
67	The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients.	
66	Bariatric surgery and perioperative anesthetic approach.	
65	Obesity and Remission Rates in Japanese Patients With Rheumatoid Arthritis Requiring Anti-Tumor Necrosis Factor Alpha Therapy. 2020 , 35, 600-608	1

64	Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?. 2021 , 9, e00890	4
63	Pharmacological Challenges in Neurocritical Care. 2020 , 73-85	
62	Evaluating Lean Liver Volume as a Potential Scaler for Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine. 2020 , 21, 746-750	1
61	Obesity-associated changes in drug pharmacokinetics. 2020 , 66, 465-471	1
60	OBEZ HASTALARDA ANTIMİKROBYAL İLAJ DOZLARI. 381-442	
59	Looking for Crumbs in the Obesity Forest: Anti-obesity Interventions and Obesity-Associated Cardiometabolic Traits in the Mexican Population. History and Systematic Review With Meta-Analyses. 2021 , 8, 665023	
58	Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review. 2020 , 46, 932-969	3
57	The paroxetine effect on exercise performance depends on the aerobic capacity of exercising individuals. 2014 , 13, 232-43	10
56	The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate. 2017 , 76, 162-165	
55	The Impact of Obesity on the Efficacy of Simvastatin for Lowering Low-Density Lipoprotein Cholesterol in a Veteran Population. 2017 , 34, 41-44	
54	Impact of Obesity on the Management of Inflammatory Bowel Disease. 2020 , 16, 350-359	
53	A prospective study of filgrastim pharmacokinetics in morbidly obese patients compared with non-obese controls. 2021 , 42, 53	
52	Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections. 2021 , 12, 754844	0
51	Antibiotic Prophylaxis in Primary and Revision Total Knee Arthroplasty. 2022 , 253-274	
50	Impact of the insertion of the clinical pharmacist in the Allogeneic Hematopoietic Stem Cells Transplantation team.. 2022 , 10781552211073797	
49	Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions.. 2022 ,	7
48	The impact of diabetes mellitus on the pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-analysis study.. 2022 , 16, 102410	1
47	Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.. 2022 ,	0

46	Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia.. 2022 , 327, 682-683		0
45	Factors influencing methotrexate and methotrexate polyglutamate in patients with rheumatoid arthritis: a systematic review of population pharmacokinetics.. 2022 ,		
44	Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia.. 2022 , 13, 1157		1
43	Pharmacokinetic determinants for the right dose of antiarrhythmic drugs.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 ,	5.5	
42	BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-inhibitors.. 2022 ,		0
41	Simultaneous Determination of Carvedilol, Enalaprilat, and Perindoprilat in Human Plasma Using LCMS/MS and Its Application to a Pharmacokinetic Pilot Study. 1		0
40	Ceftazidime dosing in obese patients: is it time for more?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 ,	5.5	0
39	Probiotic-fermented blueberry pomace alleviates obesity and hyperlipidemia in high-fat diet C57BL/6J mice. 2022 , 111396		1
38	Physiologically Based Pharmacokinetic (PBPK) Modelling. 2022 , 255-284		
37	Current Applications of Artificial Intelligence in Bariatric Surgery.		0
36	Weaker Response to XueBiJing Treatment in Severe Community-Acquired Pneumonia Patients With Higher Body Mass Index or Hyperglycemia: A Post Hoc Analysis of a Randomized Controlled Trial. 2022 , 13,		
35	Drug Disposition in Subjects with Obesity: The Research Work of Darrell R. Abernethy.		2
34	Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models. <i>Clinical Pharmacokinetics</i> ,	6.2	1
33	Utilization of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacoepidemiological Studies: A Systematic Review on Antiarrhythmic and Glucose-Lowering Medicines. 13,		
32	Antibody drug conjugates: The dos and don'ts in clinical development. 2022 , 108235		0
31	Dexamethasone exposure in normal-weight and obese hospitalized COVID -19 patients: An observational exploratory trial. <i>Clinical and Translational Science</i> ,	4.9	0
30	Vancomycin dosing in an obese patient with acute renal failure: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2022 , 10, 6218-6226	1.6	
29	Obesity and its impact on gastrointestinal health. 2022 , 1-11		

- 28 Concentrations of efavirenz, tenofovir, and emtricitabine in obesity: a cross-sectional study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2022**, Publish Ahead of Print, 3.1
- 27 Review and evaluation of vancomycin dosing guidelines for obese individuals. *Expert Opinion on Drug Metabolism and Toxicology*, 5.5
- 26 A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation. *International Journal of Clinical Pharmacy*, 2.3
- 25 Tigecycline Soft Tissue Penetration in Obese and Non-obese Surgical Patients Determined by Using In Vivo Microdialysis. **2022**, 47, 749-755
- 24 Impact of Recipient Obesity on Kidney Transplantation Outcome: A Retrospective Cohort Study with a Matched Comparison. **2022**, ○
- 23 Hepatic, Extrahepatic and Extracellular Vesicle Cytochrome P450 2E1 in Alcohol and Acetaminophen-Mediated Adverse Interactions and Potential Treatment Options. **2022**, 11, 2620 ○
- 22 Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. **2022**, 179, 103796 ○
- 21 Population Pharmacoeogenomics. **2023**, 687-694 ○
- 20 Drug-metabolizing enzymes and inflammatory responses. **2022**, 323-345 ○
- 19 Pharmakokinetik von Psychopharmaka nach Adipositaschirurgie. **2022**, 175-185 ○
- 18 Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. **2022**, 192, 110094 ○
- 17 Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. **2022**, 23, 12305 ○
- 16 Outcomes of modern antiretroviral therapy in obese individuals living with HIV. ○
- 15 Acetylsalicylic Acid Administered in Patients with Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System. **2022**, 12, 252-262 ○
- 14 Overweight and obesity affect efficacy of vaginal versus intramuscular progesterone for luteal support in vitrified-warmed blastocyst transfer. **2022**, ○
- 13 Application of a Volumetric Absorptive Microsampling (VAMS)-Based Method for the Determination of Paracetamol and Four of its Metabolites as a Tool for Pharmacokinetic Studies in Obese and Non-Obese Patients. **2022**, 61, 1719-1733 ○
- 12 Effect of obesity on the time to a successful medical abortion with misoprostol in first-trimester missed abortion. ○
- 11 Infection and obesity: Two sides of the same coin. **2023**, 73-85 ○

- 10 Effect of Azithromycin on Exacerbations in Asthma Patients with Obesity: Protocol for a Multi-Center, Prospective, Single-Arm Intervention Study. **2023**, 20, 1861 ○
- 9 Comprehensive Guidance for Antibiotic Dosing in Obese Adults: 2022 Update. ○
- 8 Drug binding and drug-drug interaction considerations in individuals with obesity before and after bariatric surgery: A retrospective cross-sectional study. **2023**, 18, 100152 ○
- 7 Challenges in Cardiovascular Evaluation and Management of Obese Patients. **2023**, 81, 490-504 ○
- 6 Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight. **2023**, 61, 106751 ○
- 5 Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. ○
- 4 Mechanisms of Obesity-Induced Changes in Pharmacokinetics of IgG in Rats. ○
- 3 Perioperative Acetaminophen Dosing in Obese Children. **2023**, 10, 625 ○
- 2 Western Diet Decreases Hepatic Drug Metabolism in Male LDLr/ApoB100/100 Mice. **2023**, 2023, 1-12 ○
- 1 The Optimal Dosing Regimen of Super Bioavailable Itraconazole in Obesity: An Experimental Rat Model Study. **2023**, ○